Effectiveness of fixed dose combination medication ('polypills') compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries.

[1]  J. Yang.  Of markets and rights: Discourse in the 2008 and 2013 Global Action Plan for the Prevention and Control of Noncommunicable Diseases , 2016 .

[2]  Samantha J. Togni,et al.  A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk , 2015, European journal of preventive cardiology.

[3]  S. Pocock,et al.  to improve adherence : results from FOCUS ( Fixed-dose Combination Drug for Secondary Cardiovascular Prevention ) Project , 2014 .

[4]  R. Doughty,et al.  Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care , 2014, BMJ : British Medical Journal.

[5]  D. Prabhakaran,et al.  Prospective meta-analysis of trials comparing fixed dose combination based care with usual care in individuals at high cardiovascular risk: the SPACE Collaboration. , 2013, International journal of cardiology.

[6]  D. Prabhakaran,et al.  Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. , 2013, JAMA.

[7]  Hendrik Koffijberg,et al.  Individual Participant Data Meta-Analysis for a Binary Outcome: One-Stage or Two-Stage? , 2013, PloS one.

[8]  A. Rodgers,et al.  The Efficacy and Tolerability of ‘Polypills’: Meta-Analysis of Randomised Controlled Trials , 2012, PloS one.

[9]  D. Prabhakaran,et al.  Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe , 2012, European journal of preventive cardiology.

[10]  S. Yusuf,et al.  Comparison of Risk Factor Reduction and Tolerability of a Full-Dose Polypill (With Potassium) Versus Low-Dose Polypill (Polycap) in Individuals at High Risk of Cardiovascular Diseases: The Second Indian Polycap Study (TIPS-2) Investigators , 2012, Circulation. Cardiovascular quality and outcomes.

[11]  R. Doughty,et al.  IMProving Adherence using Combination Therapy (IMPACT): design and protocol of a randomised controlled trial in primary care. , 2011, Contemporary clinical trials.

[12]  S. Yusuf,et al.  Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey , 2011, The Lancet.

[13]  D. Grobbee,et al.  An International Randomised Placebo-Controlled Trial of a Four-Component Combination Pill (“Polypill”) in People with Raised Cardiovascular Risk , 2011, PloS one.

[14]  Elsayed Z Soliman,et al.  A Polypill for primary prevention of cardiovascular disease: A feasibility study of the World Health Organization , 2011, Trials.

[15]  C. Reid,et al.  Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst Indigenous and non Indigenous people at high cardiovascular risk , 2010, BMC public health.

[16]  N J Wald,et al.  Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies , 2009, BMJ : British Medical Journal.

[17]  C. Cannon.  Can the polypill save the world from heart disease? , 2009, The Lancet.

[18]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[19]  S. De Geest,et al.  Adherence to Long-Term Therapies: Evidence for Action , 2003, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

[20]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[21]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.

[22]  Mark D. Huffman,et al.  Fixed-dose combination therapy for the prevention of cardiovascular disease. , 2012, The Cochrane database of systematic reviews.

[23]  D. Grobbee,et al.  [Cardiovascular polypill in high risk patients]. , 2011, Nederlands tijdschrift voor geneeskunde.

[24]  M. Law.  Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies , 2009 .

[25]  M. Helfand,et al.  Drug Class Review on HMG-CoA Reductase Inhibitors (Statins): Final Report , 2006 .